BACKGROUND: Xenotransplantation using pigs as the source species for organs carries a potential risk for transmission and activation of porcine herpesviruses. Activation of porcine cytomegalovirus (PCMV) in pig-to-baboon xenotransplantation is associated with xenograft injury and possibly an increased incidence of consumptive coagulopathy (CC). METHODS: To further investigate the role of PCMV activation in the occurrence of CC, a strategy to exclude PCMV from the donor was developed. To exclude PCMV, piglets were early-weaned and raised separated from other swine. These piglets were used as donors in an experimental protocol of pig-to-baboon heart xenotransplantation. RESULTS: Early weaning of piglets was successful in excluding PCMV. Use of PCMV-free cardiac porcine xenografts in baboons resulted in prolonged graft survival and prevented consumptive coagulopathy in all recipients. CONCLUSIONS: The use of PCMV-free cardiac grafts is beneficial in reducing the direct effects of PCMV activation in the graft (tissue damage) and the indirect effects of PCMV activation in the recipient (consumptive coagulopathy).
BACKGROUND: Xenotransplantation using pigs as the source species for organs carries a potential risk for transmission and activation of porcine herpesviruses. Activation of porcine cytomegalovirus (PCMV) in pig-to-baboon xenotransplantation is associated with xenograft injury and possibly an increased incidence of consumptive coagulopathy (CC). METHODS: To further investigate the role of PCMV activation in the occurrence of CC, a strategy to exclude PCMV from the donor was developed. To exclude PCMV, piglets were early-weaned and raised separated from other swine. These piglets were used as donors in an experimental protocol of pig-to-baboon heart xenotransplantation. RESULTS: Early weaning of piglets was successful in excluding PCMV. Use of PCMV-free cardiac porcine xenografts in baboons resulted in prolonged graft survival and prevented consumptive coagulopathy in all recipients. CONCLUSIONS: The use of PCMV-free cardiac grafts is beneficial in reducing the direct effects of PCMV activation in the graft (tissue damage) and the indirect effects of PCMV activation in the recipient (consumptive coagulopathy).
Authors: Michelle Hemann; Hui-Gang Shen; Nathan M Beach; Xiang-Jin Meng; Patrick G Halbur; Tanja Opriessnig Journal: Vet Res Commun Date: 2012-03-03 Impact factor: 2.459
Authors: Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase Journal: Transpl Immunol Date: 2018-08-06 Impact factor: 1.708
Authors: J A Shah; M S Patel; N Elias; N Navarro-Alvarez; I Rosales; R A Wilkinson; N J Louras; M Hertl; J A Fishman; R B Colvin; A B Cosimi; J F Markmann; D H Sachs; P A Vagefi Journal: Am J Transplant Date: 2017-06-06 Impact factor: 8.086
Authors: David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser Journal: Transplantation Date: 2016-10 Impact factor: 4.939
Authors: Richard N Pierson; Jay A Fishman; Gregory D Lewis; David A D'Alessandro; Margaret R Connolly; Lars Burdorf; Joren C Madsen; Agnes M Azimzadeh Journal: Circulation Date: 2020-10-05 Impact factor: 29.690